Clinical trial
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With…
NCT00044382 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00044382 |
|---|---|
| Title | Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome |
| Official title | A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 25 |
| Start date | Feb 1, 2002 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 30, 2007 |
| First posted | Aug 29, 2002 |
| Last update posted | Nov 8, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: